AtriCure
ATRC
224 hedge funds and large institutions have $1.86B invested in AtriCure in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 94 increasing their positions, 58 reducing their positions, and 21 closing their positions.
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
62% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 58
6% more funds holding
Funds holding: 211 → 224 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.66% less ownership
Funds ownership: 96.71% → 96.05% (-0.66%)
7% less capital invested
Capital invested by funds: $1.99B → $1.86B (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$22.9M |
| 2 |
Millennium Management
New York
|
+$14.6M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$10.5M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$9.44M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$80.7M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$53.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$18.4M |
| 4 |
FAM
Fred Alger Management
New York
|
-$10.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.88M |
ATRC Hedge Fund Activity: Q1 2023 in Review
224 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q1 2023, worth a combined $1.86B — down 6.7% from $1.99B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ATRC positions and 21 closed out — a net gain of 15 holders — while 94 added to existing stakes and 58 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $22.9M. The largest seller was Invesco, cutting an estimated $80.7M.
- 224 institutional investors held AtriCure (ATRC) as of Q1 2023, up from 211 in Q4 2022.
- Funds reported $1.86B of AtriCure stock for Q1 2023, down 6.7% quarter-over-quarter.
- 36 funds opened new AtriCure positions in Q1 2023 and 21 closed out, a net change of +15 holders.
- The largest AtriCure buyer in Q1 2023 was Marshall Wace, an estimated $22.9M added.
- The largest AtriCure seller in Q1 2023 was Invesco, an estimated $80.7M sold.
Based on aggregated 13F filings for Q1 2023.